BR9709077A - Compounds inhibiting matrix metalloproteinase composition having matrix metalloprotease inhibitory processes processes to inhibit matrix metalloprotease activity and to treat a mammal - Google Patents

Compounds inhibiting matrix metalloproteinase composition having matrix metalloprotease inhibitory processes processes to inhibit matrix metalloprotease activity and to treat a mammal

Info

Publication number
BR9709077A
BR9709077A BR9709077A BR9709077A BR9709077A BR 9709077 A BR9709077 A BR 9709077A BR 9709077 A BR9709077 A BR 9709077A BR 9709077 A BR9709077 A BR 9709077A BR 9709077 A BR9709077 A BR 9709077A
Authority
BR
Brazil
Prior art keywords
processes
matrix
matrix metalloprotease
mammal
treat
Prior art date
Application number
BR9709077A
Other languages
Portuguese (pt)
Inventor
Brian R Dixon
Jinshan Chen
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9709077A publication Critical patent/BR9709077A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
BR9709077A 1996-05-15 1997-05-12 Compounds inhibiting matrix metalloproteinase composition having matrix metalloprotease inhibitory processes processes to inhibit matrix metalloprotease activity and to treat a mammal BR9709077A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64502896A 1996-05-15 1996-05-15
PCT/US1997/007921 WO1997043245A1 (en) 1996-05-15 1997-05-12 Inhibition of matrix metalloproteases by acetylene containing compounds

Publications (1)

Publication Number Publication Date
BR9709077A true BR9709077A (en) 1999-08-03

Family

ID=24587368

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9709077A BR9709077A (en) 1996-05-15 1997-05-12 Compounds inhibiting matrix metalloproteinase composition having matrix metalloprotease inhibitory processes processes to inhibit matrix metalloprotease activity and to treat a mammal

Country Status (18)

Country Link
EP (1) EP0912496A1 (en)
JP (1) JP3090957B2 (en)
CN (1) CN1139570C (en)
AR (1) AR007097A1 (en)
AU (1) AU710759B2 (en)
BR (1) BR9709077A (en)
CA (1) CA2253796C (en)
CO (1) CO5080759A1 (en)
HN (1) HN1997000088A (en)
HR (1) HRP970245B1 (en)
ID (1) ID16910A (en)
PA (1) PA8429301A1 (en)
SV (1) SV1997000035A (en)
TN (1) TNSN97084A1 (en)
TW (1) TW381079B (en)
WO (1) WO1997043245A1 (en)
YU (1) YU18697A (en)
ZA (1) ZA974031B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
AR035478A1 (en) * 1999-01-27 2004-06-02 Wyeth Corp AMIDA-HYDROXAMIC ACID, ACETYLLENE, BETA-SULPHONAMIDE AND PHOSPHINIC ACID AS INHIBITORS OF TACE, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
DK2597084T3 (en) * 2010-07-08 2016-08-15 Kaken Pharma Co Ltd N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICINAL CONTAINING SAME
EP3126358A1 (en) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
WO2015150363A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids and use thereof
CA2944617A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
DE2112716A1 (en) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Biphenylyl-butyric acid derivs. - anti phlogistics
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
CA2253796C (en) 2003-10-28
HN1997000088A (en) 1997-06-18
HRP970245A2 (en) 1998-04-30
PA8429301A1 (en) 2000-05-24
CO5080759A1 (en) 2001-09-25
JP3090957B2 (en) 2000-09-25
CN1139570C (en) 2004-02-25
TW381079B (en) 2000-02-01
TNSN97084A1 (en) 2005-03-15
ZA974031B (en) 1998-02-19
WO1997043245A1 (en) 1997-11-20
AR007097A1 (en) 1999-10-13
AU710759B2 (en) 1999-09-30
EP0912496A1 (en) 1999-05-06
CN1225623A (en) 1999-08-11
HRP970245B1 (en) 2002-06-30
CA2253796A1 (en) 1997-11-20
YU18697A (en) 1999-11-22
SV1997000035A (en) 1999-01-14
ID16910A (en) 1997-11-20
AU2938697A (en) 1997-12-05
JPH11511179A (en) 1999-09-28

Similar Documents

Publication Publication Date Title
BR9509802A (en) Matrix metalloprotease inhibitors
BR9709086A (en) Matrix metalloproteinase inhibitors having matrix metalloprotease inhibitory processes Processes to inhibit matrix metalloprotease activity in a mammal and to treat a mammal
ATE257151T1 (en) HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS
DE69506219D1 (en) HYDRAULICALLY ACTUATED VALVE ARRANGEMENT
DK0873312T3 (en) Alpha-substituted arylsulfonamidohydroxamic acids as TNF-alpha and matrix metalloproteinase inhibitors
EP1079837A4 (en) Method of inhibiting membrane-type matrix metalloproteinase
NO20002469D0 (en) Aromatic sulfonic hydroxamic acid metalloprotease inhibitor
HK1020720A1 (en) Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors
BR9608586A (en) Synthetic mammal chromosome and processes for its construction
TR199903287T2 (en) Matrix metalloproteinazlar�n�n ters hydroxamate inhibitors.
DE69910953D1 (en) Active protection device for vehicles or structures
DE69808518D1 (en) ACE HEMMER / MATRIX METALLOPROTEINASE HEMMER-DRUG COMBINATIONS
BR9709902A (en) Matrix metalloproteinase inhibitors
BR9709077A (en) Compounds inhibiting matrix metalloproteinase composition having matrix metalloprotease inhibitory processes processes to inhibit matrix metalloprotease activity and to treat a mammal
BR9709084A (en) Matrix metalloproteinase inhibition composition having matrix metalloprotease inhibiting activity and processes for inhibiting matrix metalloprotease activity in a mammal and for treating mammals
NO996234L (en) Spray formulations of antihyperalgesic opiates and methods for treating topical hyperalgesic conditions and itching therewith
DE69819206D1 (en) matrix metalloproteinase
BR9708998A (en) Matrix metalloproteinase inhibition compound processes to inhibit matrix metalloprotease activity and to treat a mammal and matrix metalloprotease inhibition composition
NO307480B1 (en) Hydraulic cylinder
BR9709078A (en) Matrix metalprotease inhibition compound pharmaceutical composition and process for treating a mammal
GB9502858D0 (en) Novel use of matrix metalloproteinase inhibitors
HUP0100564A3 (en) Matrix metalloproteinase inhibitors and pharmaceuticals comprising them
GB9708133D0 (en) Novel use of matrix metalloproteinase inhibitors
ID27593A (en) TETRAHIDRONAFTILIDINIL-CARBOXAMIDE WHICH HAS ANTI-CONVULANT ACTIVITY
BR9509255A (en) Methods to inhibit discolouration of processed broccoli

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements